Initiating Intravenous Therapy
Found 9 free book(s)
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
labeling.cslbehring.com•ollow recommended venipuncture guidelines for initiating intravenous therapy. F • Administer BERINERT by slow intravenous injection at a rate of approximately 4 mL per minute. Please refer to the illustration in step 6 of the self-administration section …
HIGHLIGHTS OF PRESCRIBING INFORMATION ERBITUXsafely …
pi.lilly.comintravenous infusionone week prior to initiating a course of radiation therapy. (2.1) • Subsequent doses: 250 mg/m2 administered as a 60-minute infusion every week for the duration of radiation therapy (6–7 weeks).(2.1) • Complete ERBITUX administration 1 hour prior to radiation therapy.(2.1) • As Single-Agentor in Combination With ...
Prolia, Xgeva (denosumab) Injectable Medication ...
www.aetna.comIs the patient initiating or continuing systemic glucocorticoids at a daily dosage equivalent to 7.5 mg or greater of prednisone? ... Is the hypercalcemia of malignancy refractory to intravenous bisphosphonate therapy? Yes. Has the albumin-corrected serum calcium level been tested? Please provide the albumin-corrected serum calcium level:
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euIntravenous vedolizumab should be administered in a healthcare setting equipped to allow management of acute hypersensitivity reactions including anaphylaxis, if they occur. Appropriate ... initiating therapy with vedolizumab, unless otherwise indicated by …
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.pi.amgen.comwith CKD will require supplemental iron during the course of ESA therapy. Monitoring of Response to Therapy Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) before initiating Epogen. Following initiation of therapy and after each dose adjustment, monitor
(2.3) HIZENTRA •Infusion sites – Up to 8 infusion sites ...
labeling.cslbehring.comIf CIDP symptoms worsen on 0.4 g/kg body weight per week, consider re-initiating therapy with IGIV, while discontinuing HIZENTRA. • Monitor patient’ s clinical response and adjust duration of therapy based on patient need. Administration (2.3) •PI: Administer at regular intervals from daily up to every 2 weeks. •CIDP: Administer weekly.
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eutransplantation(induction therapy) Combination therapy with dexamethasone VELCADE 1mg powder for solution for injectionis administered via intravenous injection at the recommended dose of 1.3mg/m2 body surface area twice weekly for two weeks on days1, 4, 8, and 11in a 21-daytreatment cycle. This 3-week period is considered a treatment cycle.
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.gilead.comVEKLURY® (remdesivir) for injection, for intravenous use ... 2.1 Testing Before Initiating and During Treatment with VEKLURY 2.2 Recommended Dosage in Adults and Pediatric Patients 12 Years of Age and Older and Weighing at Least 40 kg 2.3 Renal Impairment
HIGHLIGHTS OF PRESCRIBING INFORMATION • Observe …
www.tysabri.comduration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI [see Warnings and Precautions (5.1)]. • Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML.